Sign in Subscribe

meta-analysis

A collection of 23 issues

Longitudinal toxicity analysis reveals chronic burden of cetuximab in metastatic colorectal cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Longitudinal toxicity analysis reveals chronic burden of cetuximab in metastatic colorectal cancer A pooled analysis of 1,302 patients from the ARCAD database applied a longitudinal toxicity framework to compare chemotherapy with or without cetuximab, finding that traditional single worst-grade reporting

HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases

Skip to content The CRC Digest ▸ TREATMENT HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases An updated meta-analysis of 12 studies (including 2 randomized controlled trials) encompassing more than 2,700 patients found that hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic therapy

Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer A meta-analysis of 2,023 patients analyzed prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced colorectal cancer, extracting and pooling data to analyze peritoneal metastasis-free survival, disease-free survival, and overall survival.

Immunotherapy combinations tested in pMMR/MSS rectal cancer

Skip to content The CRC Digest Immunotherapy combinations tested in pMMR/MSS rectal cancer Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist

Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype

Skip to content The CRC Digest ◆ TRIAL DATA Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not

Digital health interventions may improve nutrition and quality of life in CRC patients

Skip to content The CRC Digest ♥ LIVING WITH CRC Digital health interventions may improve nutrition and quality of life in CRC patients A systematic review and meta-analysis of randomized controlled trials found that digital health interventions showed potential to improve nutritional status and quality of life in patients with colorectal

KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic

Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases

Skip to content The CRC Digest ▸ TREATMENT Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients

KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.

Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)